Alkermes PLC (NASDAQ:ALKS) Director Richard F. Pops sold 50,000 shares of the business’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $48.87, for a total transaction of $2,443,500.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Alkermes PLC (NASDAQ ALKS) opened at $50.99 on Monday. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23.
Alkermes PLC (NASDAQ:ALKS) last posted its quarterly earnings results on Thursday, October 26th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.27%. The firm had revenue of $217.40 million during the quarter, compared to analyst estimates of $231.29 million. During the same quarter in the prior year, the business posted ($0.09) earnings per share. The company’s quarterly revenue was up 20.6% compared to the same quarter last year. equities analysts expect that Alkermes PLC will post -0.59 earnings per share for the current year.
A number of large investors have recently bought and sold shares of ALKS. Toronto Dominion Bank raised its position in Alkermes PLC by 12.7% in the second quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock worth $109,000 after purchasing an additional 212 shares in the last quarter. Daiwa SB Investments Ltd. acquired a new position in Alkermes PLC in the second quarter worth about $166,000. Greenwood Capital Associates LLC raised its position in Alkermes PLC by 1.1% in the second quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock worth $219,000 after purchasing an additional 41 shares in the last quarter. US Bancorp DE raised its position in Alkermes PLC by 366.4% in the second quarter. US Bancorp DE now owns 3,974 shares of the company’s stock worth $231,000 after purchasing an additional 3,122 shares in the last quarter. Finally, Insight Capital Research & Management Inc. acquired a new position in Alkermes PLC in the second quarter worth about $232,000. 98.19% of the stock is owned by hedge funds and other institutional investors.
A number of research firms have weighed in on ALKS. J P Morgan Chase & Co set a $78.00 target price on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Friday, October 27th. BidaskClub lowered shares of Alkermes PLC from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 9th. UBS AG set a $54.00 target price on shares of Alkermes PLC and gave the stock a “hold” rating in a research report on Friday, October 27th. Barclays PLC set a $50.00 target price on shares of Alkermes PLC and gave the stock a “hold” rating in a research report on Thursday, October 26th. Finally, Credit Suisse Group cut their target price on shares of Alkermes PLC from $70.00 to $66.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $63.55.
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
What are top analysts saying about Alkermes PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alkermes PLC and related companies.